Seattle Genetics is currently kicking up a lot of dust in the biotech industry. The Seattle based company is dominating the the Pacific Northwest region and is showing no signs of stopping. Many believe that it is highly likely the biotech giant will be acquired soon while others think it will continue to grow and expand. What ever happens in the future the company probably remain a staple in the biotech industry.
Seattle Genetics was founded 20 years ago by Dr. Clay Siegall. Siegall also serves as CEO of the company. Most of Seattle Genetics research involves human antibodies. The antibodies are studied, manipulated, and even packaged into drugs.
Seattle Genetics has been the largest biotech company in Washington for a number of years now. Its employee roster is nearing 1,000 individuals, not to mention, it is valued at around $10 billion. The company’s ultimate goal is to become a leading pharmaceutical company. If this happens it may very well become the company the Seattle community has longed for for quite some time.
While Seattle Genetics has been very successful it still has goals it has yet to reach. Dr. Clay Siegall has publicly stated that the company is emerging as global, multiproduct, oncology company dedicated to the battle against cancer. In fact, the company’s flagship drug treats Hodgkin lymphoma. Dr. Siegall says he has no interest in selling his company and instead wants to compete with larger ones. Because of Dr. Siegall’s commitment Seattle Genetics is expected to grow substantially in the coming years.
About Dr. Clay Siegall
A scientist by training Dr. Clay Siegall built his company on scientific innovation and helping patients. Prior to founding Seattle genetics he worked at Bristol-Myers Squibb Pharmaceutical Research Institute for six years. He became interested in the fight against cancer when his father was diagnosed when he was in his late teens. Since then he has been dedicated to treating cancer patients.
Dr. Siegall has been the recipient of many accolades in his 30 year career. In 2012 he was named the Pacific Northwest Ernst & Young Entrepreneur of the Year.